Title:Current use of Molecular Mechanisms and Signaling Pathways in Targeted Therapy of Prostate Cancer
Volume: 29
Issue: 34
Author(s): Vahideh Keyvani, Samaneh Mollazadeh, Nahid Kheradmand, Reihaneh Alsadat Mahmoudian, Amir Avan*Kazem Anvari*
Affiliation:
- Metabolic Syndrome Research
Center, Mashhad University of Medical Sciences, Mashhad, Iran
- College of Medicine,
University of Warith Al-Anbiyaa, Karbala, Iraq
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology (QUT), Brisbane 4059, Australia
- Department of Radiotherapy Oncology, Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Keywords:
Signaling pathways, targeted therapy, prostate cancer, molecular mechanisms, heterogeneous disease, antigen.
Abstract: Prostate cancer (PC) is identified as a heterogeneous disease. About 20 to 30% of PC patients experience
cancer recurrence, characterized by an increase in the antigen termed serum prostate-specific antigen (PSA).
Clinical recurrence of PC commonly occurs after five years. Metastatic castration-resistant prostate cancer
(mCRPC) has an intricate genomic background. Therapies that target genomic changes in DNA repair signaling
pathways have been progressively approved in the clinic. Innovative therapies like targeting signaling
pathways, bone niche, immune checkpoint, and epigenetic marks have been gaining promising results for better
management of PC cases with bone metastasis. This review article summarizes the recent consideration of
the molecular mechanisms and signaling pathways involved in local and metastatic prostate cancer, highlighting
the clinical insinuations of the novel understanding.
